Trial Profile
Phase 3 Clinical Trial of AF-0901 - Open-label study in children with status epilepticus -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2018
Price :
$35
*
At a glance
- Drugs Midazolam (Primary)
- Indications Status epilepticus
- Focus Therapeutic Use
- Sponsors Alfresa Pharma Corporation
- 24 May 2017 New trial record